Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study

By sjmartinez • May 18, 2025

Eichenfield LF, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM, Soong W, Lee LW, Devani AR, Forman SB, Siri DD, Kallender H, Angel B, Li Q, Chen X, Paller AS. Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study. J Am Acad Dermatol. 2025 May 14:S0190-9622(25)02124-3. doi: 10.1016/j.jaad.2025.05.1385. Epub ahead of print. PMID: 40378883.

Tags: atopic dermatitis, children, Dermatology, eczema, efficacy, JAK inhibitor, Janus kinase, pediatric, phase 3, Publications, randomized, ruxolitinib cream, safety, topical

TREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma

Gross L, Mutisheva I, Hillen H, Robatel S, Wartenberg M, Ma F, Bäriswyl L, Lee DJ, Modlin RL, Z'graggen K, Schenk M. TREM-1 as a[...]

New-Onset Perianal Eroded Lesion in a Pediatric Patient

Yan MJ, Galamgam J, Shen A, Mo J, Hogeling M. New-Onset Perianal Eroded Lesion in a Pediatric Patient. Pediatr Dermatol. 2025 Sep 8. doi: 10.1111/pde.70037.[...]

Systemic Corticosteroid Use in Atopic Dermatitis: A Position Paper to Inform Safer Clinical Practice and Policy

Burshtein J, Bunick CG, Vleugels RA, Armstrong AW, Golant AK, Schlesinger T, Strober BE, Song EJ, Gold LS, Lebwohl M. Systemic Corticosteroid Use in Atopic[...]